ClinicalTrials.gg
CompletedNCT05138770Updated Sep 2, 2022

Pharmacokinetics and Pharmacodynamics Clinical Study of VC005 Tablets in Healthy Subjects

A Phase 1 interventional study of VC005 Tablets and VC005 Tablets Placebo in Inflammatory Bowel Diseases, sponsored by Jiangsu vcare pharmaceutical technology co., LTD. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-02.

Sponsored by Jiangsu vcare pharmaceutical technology co., LTD · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 112 studies in Inflammatory Bowel Diseases with a site in China — 49 open to participants now, 53 under way, 5 of them phase 3. Inflammatory Bowel Diseases · China.

Enrollment
37th of 58
78 · median 97
Started
2021
with 9 others
Phase 1
13 of 112
6 open now
Registered
42nd of 112
by date

Among the 112 studies in Inflammatory Bowel Diseases with a site in China, this one is the 37th largest by enrollment of the 58 interventional ones that give a count, is one of 10 that started in 2021, is one of 13 in phase 1, and was the 42nd registered.

Inflammatory Bowel Diseases

1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

49 of the 112 studies in Inflammatory Bowel Diseases with a site in China are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 116 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Inflammatory Bowel Diseases with a site in China, or all of them as a file.
02

Study summary

This clinical trial consists of two parts:1. a randomized, double-blind, single-center, placebo-controlled, dose-escalation PK study; 2. food effects and drug metabolism transformation study.

The main purpose of this trial is to evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics and Food effects of VC005 Tablets in healthy subjects.

03

Conditions studied

  • Inflammatory Bowel Diseases

Keywords

  • healthy subjects
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female subjects aged 18 to 45 years old,inclusive
  2. Male subjects weighing at least 50 kg and female subjects weighing at least 45 kg. (BMI) between 18 and 28 kg/m2, inclusive
  3. During the trial and within 3 months after the completion of the trial (the time should exceed the time required for sperm production), there is no fertility plan, and is willing to use effective measures (non hormonal contraceptive measures) and there is no sperm donation and egg donation plan
  4. Volunteer to participate in the trial and sign an form
  5. Subjects who are able to communicate well with the investigator are willing and able to comply with all planned visits, treatment plans, laboratory examinations and other research procedures
  6. Physical examination and vital signs are normal or abnormal with no clinical significance

Exclusion criteria

Exclusion Criteria:

  1. Suspected to be allergic to the study drug or any component in the study drug, or allergic constitution
  2. abnormal with clinical significance
  3. Those who have evidence of atypical hyperplasia or a history of malignant tumor
  4. Suffer from eye diseases, including history of eye surgery or laser surgery (except laser surgery for myopia)
  5. Those who have a history of herpes simplex or herpes zoster 3 months before administration
  6. Have any history or evidence of active tuberculosis (TB) or latent TB infection (TB enzyme-linked immunospot test (T-SPOT. TB) positive), or have a history of previous skin TB test or QuantiFERON TB gold in tube test (GIT analysis) positive
  7. Known active bacteria, viruses, fungi, parasitic infections or other infections or any infections that require antibiotic treatment or hospitalization (4 weeks before screening), or any acute infections within 2 weeks of baseline
  8. Those who have participated in clinical trials of any drug or medical device (including the placebo group) within 3 months before screening
  9. Those who have been vaccinated within 2 weeks before administration, or plan to be vaccinated during the study period
  10. Those who are usually anorexia, dieting, or have started a significantly abnormal diet (such as dieting) within 4 weeks before screening; those who cannot follow a uniform diet or have difficulty swallowing
  11. Those who have undergone any surgeries within 6 months before screening
  12. Have used any prescription drugs, over-the-counter drugs, Chinese herbal medicines within 14 days before screening
  13. Those who use any drug that inhibits or induces liver enzyme activity within 28 days before administration or during the study period
  14. Those who were in blood donation within 3 months before screening and donated blood volume ≥400 mL, or received blood transfusion
  15. Those who with dyslipidemia of clinical significance and coronary heart disease
  16. Pregnant and lactating females, or females who have a positive pregnancy test
  17. Those who have difficulty in blood collection or cannot tolerate venipuncture, and those who have a history of fainting needles and bleeding
  18. Those who smoke ≥ 5 cigarettes per day within 3 months before screening and cannot stop using any tobacco products from the end of screening to before enrollment and during the test
  19. Those who drink more than 14 units of alcohol per week within 3 months prior to administration (1 unit of alcohol ≈ 360 mL beer or 45 mL 40% alcohol spirits or 150 mL wine), or those who cannot abstain from alcohol during the study
  20. Those who have taken any food or drink that affects absorption, distribution, metabolism, and excretion of the drug within 24 hours before administration, such as food or drink containing caffeine (such as chocolate) and xanthine
  21. Those who have consumed pithya , mango, grapefruit, lime, star fruit, or food or beverage prepared therefrom 2 weeks before the first administration
  22. clinical laboratory abnormalities or other clinically significant diseases (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, tumor, pulmonary, immunological, psychiatric or cardiovascular diseases)
  23. Those who are positive in urine drug and alcohol test
  24. surface antigen, antibody / hepatitis C core antigen, antigen / antibody, syphilis antibody positive
  25. Subjects with other factors not suitable for the trial considered by the investigator
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    VC005 Tablets Dose escalation groups: 1、5、10、25、50、100mg

    VC005 Tablets 1、5、10、25、50、100mg, qd

    Drug: VC005 Tablets

  • Placebo comparator
    VC005 Tablets Placebo Dose escalation groups: 1、5、10、25、50、100mg

    VC005 Tablets Placebo 1、5、10、25、50、100mg, qd

    Drug: VC005 Tablets Placebo

  • Experimental
    VC005 Tablets food effects group

    VC005 Tablets, qd

    Drug: VC005 Tablets food effects group

Interventions

  • VC005 Tablets 1、5、10、25、50、100mg single dose

  • DrugVC005 Tablets Placebo

    VC005 Tablets Placebo 1、5、10、25、50、100mg single dose

  • VC005 Tablets qd per period, for two periods

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax)

    Time frame: Day 4

  2. Area under the plasma concentration versus time curve (AUC)

    Time frame: Day 4

  3. Peak time in plasma(Tmax)

    Time frame: Day 4

  4. Accumulative urine excretion rate

    Time frame: Day 4

  5. Accumulative fecal excretion rate

    Time frame: Day 4

07

Study locations

1 site
  • The First Hospital of Jilin University
    Changchun, Jilin, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Aug 2022, 9 months.

Of 35 industry-sponsored phase 1 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 9 months is close to that.

Counting every sponsor, half of 51 studies reached it within 12 months; a quarter within 4 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2021
First posted
Dec 1, 2021
StartActual
Nov 18, 2021
Primary completionActual
Aug 26, 2022
CompletionActual
Aug 30, 2022
Last update
Sep 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05138770
Responsible party
Sponsor
First posted
Dec 1, 2021
Start date
Nov 18, 2021
Primary completion
Aug 26, 2022
Completion
Aug 30, 2022
Last update
Sep 2, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VC005

Start the discussion